CMC2.24 manufacturers
- CMC2.24
-
- $985.00
-
2026-04-22
- CAS:1255639-43-0
- Purity:
- Supply Ability: 10g
|
| | CMC2.24 Basic information |
| Product Name: | CMC2.24 | | Synonyms: | CMC2.24;4-Pentenamide, 5-(4-hydroxyphenyl)-2-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-3-oxo-N-phenyl-, (4E)-;CMC2.24,CMC-2.24;(2E,4E)-3-Hydroxy-5-(4-hydroxyphenyl)-2-((E)-3-(4-hydroxyphenyl)acryloyl)-N-phenylpenta-2,4-dienamide;(4E)-5-(4-Hydroxyphenyl)-2-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-3-oxo-N-phenyl-4-pentenamide | | CAS: | 1255639-43-0 | | MF: | C26H21NO5 | | MW: | 427.45 | | EINECS: | | | Product Categories: | | | Mol File: | 1255639-43-0.mol |  |
| | CMC2.24 Chemical Properties |
| Boiling point | 711.1±60.0 °C(Predicted) | | density | 1.345±0.06 g/cm3(Predicted) | | storage temp. | -20°C, protect from light | | solubility | DMSO : < 1 mg/mL (insoluble or slightly soluble) | | form | Solid | | pka | 8.28±0.59(Predicted) | | color | Light yellow to orange |
| | CMC2.24 Usage And Synthesis |
| Uses | CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC50s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis[1][2][3]. | | in vivo | CMC2.24 (50 mg/kg; p.o.; five times per week during 17 days) inhibits the growth of pancreatic cancer xenografts[1].
CMC2.24 inhibits the growth of human PC through a strong cytokinetic effect. CMC2.24 inhibits ERK signaling pathway in PC cells and xenografts[1]. | Animal Model: | Female immune deficient BALB/c nude mice[1] | | Dosage: | 50 mg/kg | | Administration: | P.o.; five times per week during 17 days | | Result: | Reduced the rate of growth over baseline by 66.9%.
|
| | IC 50 | RAS; MMP-1: 69.8 μM (IC50); MMP-2: 4.8 μM (IC50); MMP-3: 2.9 μM (IC50); MMP-7: 5 μM (IC50); MMP-8: 4.5 μM (IC50); MMP-9: 8 μM (IC50); MMP-12: 2 μM (IC50); MMP-13: 2.7 μM (IC50); MMP-14: 15.3 μM (IC50) | | References | [1] Mallangada NA, et al. A novel tricarbonylmethane agent (CMC2.24) reduces human pancreatic tumor growth in mice by targeting Ras. Mol Carcinog. 2018;57(9):1130-1143. DOI:10.1002/mc.22830
[2] Zhou Y, et al. Chemically modified curcumin (CMC2.24) alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis. J Mol Med (Berl). 2020;98(10):1479-1491. DOI:10.1007/s00109-020-01972-1
[3] Zhang Y, et al. Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem. 2012;19(25):4348-4358. DOI:10.2174/092986712802884295 |
| | CMC2.24 Preparation Products And Raw materials |
|